Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: An open-label pilot study

Infliximab was more effective than azathioprine in reducing histological, but not endoscopic and clinical recurrence after curative ileocolonic resection in “high risk” CD patients.